DOA
VNDA icon

D'Orazio & Associates’s Vanda Pharmaceuticals VNDA Stock Holding History

D'Orazio & Associates’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,500
Closed -$23K – 345
2017
Q4 		$23K Buy
1,500
+1,000
+200% +$14.8K 0.01% 172
2017
Q3 		$9K Sell
500
-1,000
-67% -$16.7K ﹤0.01% 204
2017
Q2 		$24K Buy
1,500
+1,000
+200% +$14.4K 0.01% 180
2017
Q1 		$7K Buy
+500
New +$7.13K ﹤0.01% 242

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

D'Orazio & Associates's VNDA Position: Q1 2018 in Review

D'Orazio & Associates sold out of Vanda Pharmaceuticals (VNDA) in Q1 2018, closing a stake of 1,500 shares — an estimated $23K sold.

D'Orazio & Associates first reported a position in VNDA in Q1 2017 and held it in 4 quarters. The position peaked at $24K in Q2 2017. 131 funds tracked by Wall St. Rank hold VNDA as of Q1 2018.

  • D'Orazio & Associates reported no remaining Vanda Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • D'Orazio & Associates sold 1,500 Vanda Pharmaceuticals shares in Q1 2018, an estimated $23K.
  • D'Orazio & Associates first reported a position in Vanda Pharmaceuticals in Q1 2017 and held it in 4 quarters.
  • D'Orazio & Associates's Vanda Pharmaceuticals position peaked at $24K in Q2 2017.
  • 131 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2018.

Based on D'Orazio & Associates's 13F filing for Q1 2018, filed 4 May 2018.